title: Enhancement of specific cellular immune response induced by DNA vaccines encoding PML-RARalpha and hIL-2 genes.
abstract: A DNA vaccine encoding PML-RAR alpha fusion gene is thought to be a promising approach for acute promyelocytic leukemia patients to enhance immune responses after attaining complete remission. In this study, we sought to enhance cellular immunity by coexpressing human interleukin (hIL)-2 genes. Successfully constructed plasmids PML-RAR alpha-hIL-2-pIRES, PML-RAR alpha-pIRES and hIL-2-pIRES were delivered intramuscularly in BALB/C mice at 14-day intervals for three cycles. The cellular immune responses with respect to the specific cytotoxicity of spleen cells; interferon-gamma secretion in sera, and the T-cell receptor rearrangement excision circles of thymocyte were significantly increased from PML-RARalpha-hIL-2-pIRES immunized mice. Our results indicate that a DNA vaccine with PML fusion gene segment and hIL-2 together might elicit increased cellular immune responses in mice.
authors.affiliation: Institute of Hematology, Medical College, Jinan University, Guangzhou, China.
authors.forename: Dongzhi
authors.initials: D
authors.lastname: Cen
authors.forename: Gang
authors.initials: G
authors.lastname: Hu
authors.forename: Yubing
authors.initials: Y
authors.lastname: Zhou
authors.forename: Lijian
authors.initials: L
authors.lastname: Yang
authors.forename: Shaohua
authors.initials: S
authors.lastname: Chen
authors.forename: Christian A
authors.initials: CA
authors.lastname: Schmidt
authors.forename: Yangqiu
authors.initials: Y
authors.lastname: Li
mesh_terms: D000818:Animals; D045744:Cell Line, Tumor; D003601:Cytotoxicity Tests, Immunologic; D015329:Gene Rearrangement, T-Lymphocyte; D005822:Genetic Vectors / Q000008:administration & dosage; D006801:Humans; D007111:Immunity, Cellular; D007114:Immunization; D007273:Injections, Intramuscular; D007371:Interferon-gamma / Q000378:metabolism; D007376:Interleukin-2 / Q000235:genetics / Q000276:immunology*; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D018482:Muscle, Skeletal / Q000276:immunology / Q000648:ultrastructure; D015514:Oncogene Proteins, Fusion / Q000235:genetics / Q000276:immunology*; D011897:Random Allocation; D011993:Recombinant Fusion Proteins / Q000235:genetics / Q000276:immunology; D013154:Spleen / Q000166:cytology / Q000276:immunology; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology; D019444:Vaccines, DNA / Q000008:administration & dosage / Q000276:immunology*
chemical_list: D007376:Interleukin-2; D015514:Oncogene Proteins, Fusion; D011993:Recombinant Fusion Proteins; D019444:Vaccines, DNA; C093476:promyelocytic leukemia-retinoic acid receptor alpha fusion oncoprotein; D007371:Interferon-gamma